• IgGenix Announces $25M in Series A1 Funding firstwordpharma
    July 28, 2021
    IgGenix, Inc., a biotechnology company taking a revolutionary approach to directly address allergic disease, today announced that it has raised $25 million in an oversubscribed Series A1 financing.
PharmaSources Customer Service